Refine your search
Collections
Co-Authors
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Simant, Kumar
- Interleukin-6, a major player of cytokine storm in COVID-19 and its alleviation by therapeutic antibodies
Abstract Views :154 |
PDF Views:80
Authors
Affiliations
1 Centre for BioSeparation Technology, Vellore Institute of Technology, Vellore 632 014, India
1 Centre for BioSeparation Technology, Vellore Institute of Technology, Vellore 632 014, India
Source
Current Science, Vol 123, No 6 (2022), Pagination: 745-753Abstract
Interleukin-6 (IL-6) is an important cytokine that plays a vital role in immune response and inflamma-tion. Here, the signalling functions of IL-6 through its receptors, physiological and pathological roles, espe-cially its contribution to various autoimmune diseases, cancers and severe COVID-19/SARS-CoV2 infections are described. It is reported that in severe COVID-19 infection and auto-immune diseases, the patients expe-rience cytokine storms due to hyper-activation of the IL-6 receptor pathway leading to detrimental effects. Blocking IL-6 receptor action by therapeutic antibodies has been considered an attractive strategy of treat-ment. The latest findings on the application of anti-IL-6 therapeutic antibodies in COVID-19 patients are also discussed.Keywords
COVID-19 infection, cytokine storm, im-mune response, interleukin-6, therapeutic antibodies.Full Text
References
- Kumar, P. and Mina, U., Life Sciences: Fundamentals and Practice-1 (Fifth Edition), Pathfinder Publication, New Delhi, 2015, pp. 459–534.
- World Health Organization, WHO coronavirus (COVID-19) dash-board with vaccination data; https://covid19.who.int/ (accessed on 10 June 2022).
- Tang, Y. et al., Cytokine storm in COVID-19: the current evidence and treatment strategies. Front. Immunol., 2020, 11, 1708.
- Atal, S. and Fatima, Z., IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharma. Med., 2020, 34, 223– 231.
- Fajgenbaum, D. C. and June, C. H., Cytokine storm. N. Engl. J. Med., 2020, 383, 2255–2273.
- Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L. and Sekhon, M. S., Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur. Respir. J., 2020, 56, 2003006.
- Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L. and Borca, M. V., The role of interleukin-6 during viral infections. Front. Microbiol., 2019, 10, 1057.
- Wojdasiewicz, P., Poniatowski, A. A. and Szukiewicz, D., The role of inflammatory and anti-inflammatory cytokines in the patho-genesis of osteoarthritis. Med. Inflamm., 2014, 2014, 561459; doi: 10.1155/2014/561459.
- Chalaris, A., Garbers, C., Rabe, B., Rose-John, S. and Scheller, J., The soluble interleukin-6 receptor: generation and role in inflam-mation and cancer. Eur. J. Cell Biol., 2011, 90, 484–494.
- Brocke-Heidrich, K. et al., Interleukin-6-dependent gene expres-sion profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood, 2004, 103, 242–251.
- Wongchana, W. and Palaga, T., Direct regulation of interleukin-6 expression by Notch signaling in macrophages. Cell. Mol. Immu-nol., 2012, 9, 155–162.
- Jones, S. A. and Jenkins, B. J., Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature Rev. Immunol., 2018, 18, 773–789.
- Kang, S., Narazaki, M., Metwally, H. and Kishimoto, T., Historical overview of the interleukin-6 family cytokine. J. Exp. Med., 2020, 217, 20190347.
- Murakami, M. and Hirano, T., The pathological and physiological roles of IL-6 amplifier activation. Int. J. Biol. Sci., 2012, 8, 1267–1280.
- Ohsugi, Y., The immunobiology of humanized Anti-IL6 receptor antibody: from basic research to breakthrough medicine. J. Transl. Autoimmun., 2020, 3, 100030.
- Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M. and Shiina, M., IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci., 2012, 122, 143–159.
- Castell, J. V. et al., Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett., 1989, 242, 237–239.
- Ebrabem, Q., Minamoto, A., Hoppe, G., Anand-Apte, B. and Sears, J. E., Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest. Ophthalmol. Vis. Sci., 2006, 47, 4935–4941.
- Fielding, C. A. et al., IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol., 2008, 181, 2189–2195.
- Tanaka, T., Narazaki, M. and Kishimoto, T., IL-6 in inflammation, immunity, and disease. Cold Spring Harbour Perspect. Biol., 2014, 6, 1–16.
- Väänänen, H. K. and Härkönen, P. L., Estrogen and bone meta-bolism. Maturitas, 1996, 23, S65–S69.
- Poli, V. et al., Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J., 1994, 13, 1189–1196.
- Nakajima, S. et al., Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells. Cytokine, 2009, 47, 91–97.
- Tsuchida, A. I. et al., Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model. Arthritis Res. Ther., 2012, 14, R262.
- Feldmann, M., Brennan, F. M. and Maini, R. N., Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol., 1996, 14, 397–440.
- Kishimoto, T., Kang, S. and Tanaka, T., IL-6: a new era for the treatment of autoimmune inflammatory diseases. In Innovative Medicine, Springer, Japan, 2015, pp. 131–147; doi:10.1007/978-4-431-55651-0_11.
- Dougados, M. et al., Adding tocilizumab or switching to tocili-zumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis., 2013, 72, 43–50.
- Sandborg, C. and Mellins, E. D., A new era in the treatment of systemic juvenile idiopathic arthritis. N. Engl. J. Med., 2012, 367, 2439–2440.
- Tackey, E., Lipsky, P. E. and Illei, G. G., Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus, 2004, 13, 339–343.
- Krei, K., Fredrikson, S., Fontana, A. and Link, H., Interleukin-6 is elevated in plasma in multiple sclerosis. J. Neuroimmunol., 1991, 31, 147–153.
- Ashtari, F., Madanian, R., Shaygannejad, V., Zarkesh, S. H. and Ghadimi, K., Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects. Int. J. Physiol. Pathophysiol. Pharmacol., 2019, 11, 267.
- Masjedi, A. et al., The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed. Pharmacother., 2018, 108, 1415–1424.
- Bromberg, J. and Wang, T. C., Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell, 2009, 15, 79–80.
- Yang, X. et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med., 2020, 8, 475–481.
- Abbasifard, M. and Khorramdelazad, H., The bio-mission of inter-leukin-6 in the pathogenesis of COVID-19: a brief look at potential therapeutic tactics. Life Sci., 2020, 257, 118097.
- Huang, C. et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395, 497–506.
- Conti, P. et al., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents, 2020, 34, 327–331.
- Martinez, N. E. et al., Regulatory T cells and Th17 cells in viral infections: implications for multiple sclerosis and myocarditis. Future Virol., 2012, 7, 593–608.
- Lauder, S. N. et al., Interleukin-6 limits influenza-induced inflam-mation and protects against fatal lung pathology. Eur. J. Immunol., 2013, 43, 2613–2625.
- Hashizume, M., Outlook of IL-6 signaling blockade for COVID-19 pneumonia. Inflamm. Regen., 2020, 40, 24.
- Scherger, S., Henao-Martínez, A., Franco-Paredes, C. and Shapiro, L., Rethinking interleukin-6 blockade for treatment of COVID-19. Med. Hypotheses, 2020, 144, 110053.
- US National Library of Medicine, Anti-IL6 treatment of serious COVID-19 disease with threatening respiratory failure, sponsored by Henriksen, M., 2020; https://www.clinicaltrials.gov/ct2/show/NCT- 04322773
- Luo, P. et al., Tocilizumab treatment in COVID-19: a single center experience. J. Med. Virol., 2020, 92, 814–818.
- Samaee, H., Mohsenzadegan, M., Ala, S., Maroufi, S. S. and Mora-dimajd, P., Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. Int. Immunopharmacol., 2020, 89, 107018.
- Stone, J. H. et al., Efficacy of tocilizumab in patients hospitalized with COVID-19. N. Engl. J. Med., 2020, 383, 2333–2344.
- Salama, C. et al., Tocilizumab in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med., 2021, 384, 20–30.
- Lomakin, N. V. et al., The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflamm. Res., 2021, 70(10–12), 1233–1246.
- Reichert, J., Anti-IL-6R levilimab registered as COVID-19 treatment in Russia – The Antibody Society, 2020; https://www.antibody-society.org/approvals/anti-il-6r-levilimab-registered-as-covid-19-treat-ment-in-russia/
- Basu, M., Russia approves levilimab for treating severe Covid-19 patients, says it reduces death risk, 2020; https://theprint.in/ health/russia-approves-levilimab-for-treating-severe-covid-19-pati-ents-says-it-reduces-death-risk/439094/
- Shaw, S. et al., Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs, 2014, 6, 773.
- Antonov, V. N. et al., Experience of olokizumab use in COVID-19 patients. Тherapeutic Archive, 2020, 92, 148–154.
- Della-Torre, E. et al., Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann. Rheum. Dis., 2020, 79, 1277–1285.
- Genovese, M. C. et al., Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol., 2015, 67, 1424–1437.
- US National Library of Medicine, A study to evaluate the efficacy and safety of sirukumab in confirmed severe or critical confirmed coronavirus disease (COVID-19), sponsored by Janssen Biophar-maceuticals, 2021; https://www.clinicaltrials.gov/ct2/show/study/ NCT04380961
- Luo, P. et al., Tocilizumab treatment in COVID-19: a single center experience. J. Med. Virol., 2020, 92(7), 814–818.
- US National Library of Medicine, Study of the efficacy and safety of a single administration of olokizumab and RPH-104 with standard therapy in patients with severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2) infection (COVID-19), sponsored by R-Pharma International, LLC, 2022; https://clinicaltrials.gov/ct2/show/ NCT04380519
- US National Library of Medicine, Sarilumab COVID-19, sponsored by Sanofi, 2021; https://clinicaltrials.gov/ct2/show/NCT04327388